CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This was a prospective, single arm, phase 2 trial. Adult Patients with histologically
confirmed locally advanced cervical cancer were enrolled to receive the treatment of
concurrent chemoradiotherapy combined with Endostar. The primary endpoint was
progression-free survival (PFS) rate at 1 year. The secondary endpoints were PFS, overall
survival (OS) and safety.